PATTERNS OF SECOND-LINE (2L) TREATMENT FOR METASTATIC UROTHELIAL CANCER (MUC) IN CANADA

Author(s)

Jaffe DH1, DeCongelio M2, Li VW2, Lakhdari K3, Goulden S4, Gooden KM5
1Kantar Health, Tel Aviv, Israel, 2Kantar Health, New York, NY, USA, 3Bristol-Myers Squibb Canada, Montréal, QC, Canada, 4Bristol-Myers Squibb, Uxbridge, UK, 5Bristol-Myers Squibb, Lawrenceville, NJ, USA

Presentation Documents

OBJECTIVES : Examine treatment patterns of patients receiving 2L treatment for mUC in Canada.

METHODS : A retrospective, non-interventional study was conducted among 25 Canadian physicians. Data were collected from medical charts of patients who started and stopped 2L treatment for mUC within 2 years of data collection. 2L was defined as treatment after progression/recurrence following first-line (1L) treatment, or recurrence ≤12 months of neoadjuvant/adjuvant treatment.

RESULTS :

Conference/Value in Health Info

2018-05, ISPOR 2018, Baltimore, MD, USA

Value in Health, Vol. 21, S1 (May 2018)

Code

PCN187

Topic

Health Service Delivery & Process of Care

Topic Subcategory

Prescribing Behavior, Treatment Patterns and Guidelines

Disease

Urinary/Kidney Disorders

Explore Related HEOR by Topic

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×